# A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis

> **NCT05832151** · PHASE2 · COMPLETED · sponsor: **CinDome Pharma, Inc.** · enrollment: 382 (actual)

## Conditions studied

- Diabetic Gastroparesis

## Interventions

- **DRUG:** CIN-102 Dose 15mg or 10mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05832151
- **Lead sponsor:** CinDome Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-27
- **Primary completion:** 2025-11-14
- **Final completion:** 2025-12-12
- **Target enrollment:** 382 (ACTUAL)
- **Last updated:** 2025-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05832151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05832151, "A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05832151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*